The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.
about
Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeysIn vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives.The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeysNociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Orphan GPCR research.Select G-protein-coupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and β-arrestin 1 pathway.Development of nociceptin receptor (NOP) agonists and antagonists.Recently patented and promising ORL-1 ligands: where have we been and where are we going?UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.Cebranopadol: novel dual opioid/NOP receptor agonist analgesic.Targeting multiple opioid receptors - improved analgesics with reduced side effects?In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.Novel Synthesis and Pharmacological Characterization of NOP Receptor Agonist 8-[(1S,3aS)-2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (Ro 64-6198)Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.
P2860
Q24647780-A139D38A-7D91-477C-AA74-2F5F85EF73A6Q34571432-28AFD12C-31E9-4F84-921F-46F3699ED5B8Q35026981-E8A875E5-0EB1-43D9-97B8-209D629C7611Q36744366-D9F878CD-D3A5-4D0A-8A41-19B429B52D1BQ37028758-716CCF99-5CE1-4F2D-9CB1-4D0F86501E75Q37409861-592C785F-4BE2-494B-A9D7-EF1942BD5D17Q37680813-87642D93-D50E-42A8-98D0-C919267B010AQ37697788-9A48C547-5DAE-41E8-8700-C3C8B9C39F17Q37760247-E1D6D5DF-314C-4A90-A89E-94C0A9B99CB0Q38217456-09C9EB6A-0A51-4B1B-90F8-8C04CB7E252AQ38990121-C8906073-C5CA-4DCA-9F12-4E6B994B44CAQ39221109-D38ADB9D-C84E-449E-ACDE-09BAD73DAF83Q41380155-A8634F8A-5431-4458-A436-7AEAC30085A8Q41493064-C86DEB9F-B9BD-46B2-B487-183F8C7151A2Q41525142-242D31EE-CA0E-4A04-84B8-BD79FE8A1F1CQ48016277-092AA012-9583-491E-9FBB-74E912D6BA3B
P2860
The pharmacology of Ro 64-6198, a systemically active, nonpeptide NOP receptor (opiate receptor-like 1, ORL-1) agonist with diverse preclinical therapeutic activity.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@ast
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@en
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@nl
type
label
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@ast
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@en
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@nl
prefLabel
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@ast
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@en
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@nl
P2860
P1476
The pharmacology of Ro 64-6198 ...... clinical therapeutic activity.
@en
P2093
James R Shoblock
P2860
P304
P356
10.1111/J.1527-3458.2007.00007.X
P577
2007-01-01T00:00:00Z